These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 498414)

  • 1. Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.
    Beran M; Andersson B; Eksborg S; Ehrsson H
    Cancer Chemother Pharmacol; 1979; 2(1):19-24. PubMed ID: 498414
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.
    Schölzel C; van Putten W; Löwenberg B
    Leuk Res; 1986; 10(12):1455-9. PubMed ID: 3467144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effects of the lysosomotropic agents DNA-ellipticine, DNA-daunorubicin, and DNA-ellipticine:daunorubicin on L1210 leukemia cells.
    Sorace RA; Sheid B
    Cancer Treat Rep; 1979 Jan; 63(1):43-51. PubMed ID: 421232
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of the drug sensitivity of acute nonlymphocytic leukaemia using the in vitro clonogenic assay.
    Preisler HD; Azarnia N
    Br J Haematol; 1984 Dec; 58(4):633-40. PubMed ID: 6518136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
    Gustavsson A; Olofsson T
    Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition by chemotherapeutic agents of human bone marrow progenitor cells and clonogenic cells of a lymphoblastic cell line.
    Williams CK; Ohnuma T; Holland JF
    Eur J Cancer (1965); 1981 May; 17(5):519-26. PubMed ID: 6975210
    [No Abstract]   [Full Text] [Related]  

  • 8. [Leukemic bone marrow stromal cells in vitro protect leukemic cell line Jurkat cells from daunorubicin-induced apoptosis].
    Li ZJ; Teng BX; Chen XH; Kong PY; Wang JG; Peng XG; Yang ZZ
    Ai Zheng; 2005 Jun; 24(6):672-5. PubMed ID: 15946476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.
    Eksborg S; Ehrsson H; Andersson B; Beran M
    J Chromatogr; 1978 Jun; 153(1):211-8. PubMed ID: 659557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin.
    Andersson B; Beran M; Peterson C; Tribukait B
    Cancer Res; 1982 Jan; 42(1):178-83. PubMed ID: 7053847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].
    Lei HY; Zhao XL; Xiao XB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):503-4. PubMed ID: 15972152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia.
    Marie JP; Zittoun R; Delmer A; Thevenin D; Suberville AM
    Leukemia; 1987 Feb; 1(2):121-6. PubMed ID: 3478535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents.
    Spiro TE; Mattelaer MA; Efira A; Stryckmans P
    J Natl Cancer Inst; 1981 Jun; 66(6):1053-9. PubMed ID: 6941040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Chemother Pharmacol; 1979; 2(1):43-7. PubMed ID: 498419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal and leukemic hemopoiesis compared.
    McCulloch EA; Buick RN; Till JE
    Cancer; 1978 Aug; 42(2 Suppl):845-53. PubMed ID: 278636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An in vitro chemotherapy sensitivity test on leukemic colony-forming cells (L-CFU) and its clinical evaluation].
    Moriyama Y; Urushiyama M; Hirosawa H; Koyama S; Takai K; Fujiwara M; Kishi K; Takahashi M; Sakai C; Sanada M; Shibata A
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1749-54. PubMed ID: 7184371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-cycle disturbance and induction of programmed death by new formamidine analogs of daunorubicin.
    Stojak M; Lukawska M; Oszczapowicz I; Opydo-Chanek M; Mazur L
    Anticancer Res; 2014 Dec; 34(12):7151-8. PubMed ID: 25503143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic colony (L-CFU) formation in vitro: clinical correlations of the in vitro growth pattern of L-CFU and drug sensitivity in acute leukemia.
    Moriyama Y; Sanada M
    Nihon Ketsueki Gakkai Zasshi; 1983 Dec; 46(7):1583-8. PubMed ID: 6675406
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of cytostatic drugs on the kinetics of leukemic blast cells in man.
    Killmann SA
    Schweiz Med Wochenschr; 1974 Feb; 104(8):278-84. PubMed ID: 4814680
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631.
    Villamarín S; Mansilla S; Ferrer-Miralles N; Priebe W; Portugal J
    Eur J Biochem; 2003 Feb; 270(4):764-70. PubMed ID: 12581216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.